Quince Therapeutics Files 8-K with Material Agreement
Ticker: QNCX · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-update
Related Tickers: QNCE
TL;DR
Quince Therapeutics (QNCE) filed an 8-K on 6/12/25, reporting a material definitive agreement and equity sales.
AI Summary
On June 12, 2025, Quince Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Quince Therapeutics, Inc. was formerly known as Cortexyme, Inc. until January 4, 2016.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and potential equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Registrant
- Cortexyme, Inc. (company) — Former company name
- June 12, 2025 (date) — Date of earliest event reported
- January 4, 2016 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement entered into by Quince Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into on June 12, 2025.
What type of equity securities were sold unregistered?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
What are the key financial statements and exhibits being filed?
The filing indicates that financial statements and exhibits are being filed, but the specific content is not detailed in this summary.
When did Quince Therapeutics change its name from Cortexyme, Inc.?
Quince Therapeutics, Inc. changed its name from Cortexyme, Inc. on January 4, 2016.
What is the principal executive office address for Quince Therapeutics, Inc.?
The principal executive offices are located at 611 Gateway Boulevard, Suite 273, South San Francisco, California, 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Quince Therapeutics, Inc. (QNCX).